%D8%B1%D9%8A%D9%81%D8%A7%D9%83%D8%B3%D9%8A%D9%85%D9%8A%D9%86%D8%B1%DB%8C%D9%81%D8%A7%D9%88%DA%A9%D8%B3%DB%8C%D9%85%DB%8C%D9%86RifaximinRifaximinRifaximina%D8%B1%DB%8C%D9%81%D8%A7%DA%A9%D8%B3%DB%8C%D9%85%DB%8C%D9%86RifaximinRifaximina%D0%A0%D0%B8%D1%84%D0%B0%D0%BA%D1%81%D0%B8%D0%BC%D0%B8%D0%BDRyfaksyminaRifaximin%C4%83RifaksiminRifaksimin%D0%A0%D0%B8%D1%84%D0%B0%D0%BA%D1%81%D0%B8%D0%BC%D1%96%D0%BDRifaximinQ416073%E5%88%A9%E7%A6%8F%E6%98%94%E6%98%8E
about
P3781
Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled TrialStudy of Rifaximin in Minimal Hepatic EncephalopathyRifaximin as a Modulator of Microbial Translocation and Immune ActivationRifaximin to Modify the Disease Course in Sickle Cell DiseasePharmacodynamics, Safety and Pharmacokinetics of the Oral Administration MNK6106 (L-ornithine Phenylacetate) vs Rifaximin in Participants With Hepatic Cirrhosis and a History of Prior Episodes of Hepatic EncephalopathyRifaximin-treatment of Collagenous ColitisA Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence PreventionRifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy VolunteersRifaximin for Prevention of Travellers' DiarrheaTwo Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With AscitesA Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT ScansRifaximin Treatment of Papulopustular RosaceaRifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal CancerThe Effect of Rifaximin on Portal Vein ThrombosisMicrobiota Intervention to Change the Response of Parkinson's DiseaseHydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant DiarrheaRole of Methane in Glycemic ControlEffect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic EncephalopathyRifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 DiabetesEfficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF DevelopmentRifaximin and Norfloxacin for Prevention of SBP in Adults With Decompensated CirrhosisRifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized TrialRifaximin for the Treatment of Persistent Symptoms in Patients With Celiac DiseaseWeight Loss in Parkinson's Disease and Role of Small Bowel Bacterial OvergrowthRifaximin for Functional DyspepsiaImpact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver DiseaseRifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver TransplantIntestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With CirrhosisSafety Study for Patients With a History of Hepatic EncephalopathyRifaximin in Patients With Monoclonal GammopathyModulation of Gut Microbiota by Rifaximin in PD PatientsA Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal FailureRifaximin Predicts the Complications of Decompensated CirrhosisImmunohistology in USDD and Correlation Between Bacterial Flora and PhlogosisRandomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic EncephalopathyRifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPSRifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic PatientsThe Effects of Rifaximin Therapy in Irritable Bowel Syndrome
P4844
Antibiotics for the treatment of hepatic encephalopathyRifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathyImpact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers.Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis.Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysisRifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286.Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.Rifaximin in irritable bowel syndrome: rationale, evidence and clinical useRifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-AnalysisLactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?The role of antimicrobials in Crohn's disease.Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis.Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease.The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients.Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.Proteome profiles of vaginal fluids from women affected by bacterial vaginosis and healthy controls: outcomes of rifaximin treatment.Toxic epidermal necrolysis associated with rifaximin.Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin.One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study.Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis.Rifaximin in the treatment of recurrent Clostridium difficile infection.A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.The effect of rifaximin on gut flora and Staphylococcus resistance.Relevant role of efflux pumps in high levels of rifaximin resistance in Escherichia coli clinical isolates.Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017.A multicenter, double-blind, randomized, placebo-controlled study of rifaximin for the treatment of bacterial vaginosisRifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in MiceUnderstanding the impact of neurologic complications in patients with cirrhosisCurrent and future pharmacological therapies for managing cirrhosis and its complicationsCyclic rifaximin therapy effectively prevents the recurrence of symptoms after exacerbation of symptomatic uncomplicated diverticular disease: a retrospective studyLong-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosisRifaximin for preventing acute graft-versus-host disease: impact on plasma markers of inflammation and T-cell activation▾Rifaximin for the treatment of travellers' diarrhoea?Treatment of Acute Hepatic Encephalopathy: Comparing the Effects of Adding Rifaximin to Lactulose on Patient Outcomes
P921
Q61729696-9C63226F-DBD6-44CC-8456-0B5EA21956A7Q61934458-32E9E0BC-F626-4527-94DF-0299F979269CQ61938962-85DD1292-238F-4053-BCB8-E1E60026AA0DQ61956302-6C891FF4-D128-4CC5-B535-25950D3F511AQ62040079-711DAEC3-23B8-410B-832E-05091583F23AQ62041699-92C1FEC8-9AF8-4EF3-946A-77BB37E1520AQ62062496-6DDEC480-0441-4C4F-B0EF-A236D69C4192Q62813708-8E4E2C4B-15F6-4FF5-A642-57F66ED0539DQ62818407-60A73505-388F-49DD-9181-BB8060E89B85Q63062427-96E4016F-67BD-4870-AAC1-463BAF45CBD3Q63062582-116E5E6E-3267-48AA-8448-EE8342F24274Q63229207-704352FC-6425-4B83-9804-36D9BCE9AE89Q63318491-8B16DB11-C73A-4218-AC58-1AE988D316E0Q63335774-20E5A1BC-98DB-4D5D-93AD-83E5850A9601Q63336451-08D80334-E991-4C59-940A-DAF75C4849E4Q63394878-52E6CBDC-325E-4D17-AEB4-657D63B7A039Q63396913-266B2F54-89C1-4E8B-9EE7-46550F554B3CQ63573321-16C952EF-689B-41FC-B5D2-F1AB318C5917Q63575906-1EE95B2C-7D7F-487B-A35E-DD35042EAC4EQ63590713-4C6F4030-8B03-4F5C-993E-B5A7FEE4DF40Q63593107-0E0C5835-5DD0-4E2D-B370-1E05B70F32E2Q63594316-CB6E4373-FC84-4AF8-85E3-14FFBE9DEA01Q63598614-D109E524-D7B8-439B-A16A-86A60DF7A32EQ63818104-E585D1A4-ADE8-4550-8D5D-33A7A947016FQ63833408-04B89548-FE26-4030-94D0-8A6D84E6B4EAQ63838837-F586EACB-7F9D-4FF5-892B-44E80848AEA1Q63841488-5B4395F4-3948-4B38-9E67-B8390F673CEDQ63841909-6FE27334-6545-4A58-98C0-6D04B96A31C1Q63843704-42CA7647-0DDB-45B4-B385-6D57A1095DF3Q63844579-6B2D6BD7-E2AA-42AE-ABC8-DBC5D453D2B4Q64045613-A7149450-2DE7-4C39-B0E8-DD38B9491943Q64150332-0FE8677D-9026-4FAF-9BA2-C61C7FF24C25Q64151328-F0474E34-F29C-4514-AC67-6B684EB1784CQ64221369-1CDF1875-E169-4723-BF31-26A0C060DB0DQ64222416-E40925C6-368D-47D5-92B4-B18722802C3BQ64222865-B16A5611-A0BC-4772-989E-2FE1F6A60640Q64350412-CA525D42-A551-499F-83A0-937A66E3B1D6Q64350694-3813CCC5-AEA7-48C3-AF44-230873D24EA0Q64351040-E5AC346B-B215-4322-8A7C-690D120B92E5Q64351215-FBAD1CE9-3032-4108-A59D-7043CE55892D
P4844
Q27012878-C571AC63-3886-40DE-9804-37A9F1662A3EQ33458234-726611A1-CB11-4FC1-836B-709A7399C38EQ34658087-63CCC170-71F4-4170-8B80-A1BB684533FCQ34757166-10833CB2-A657-4114-86AE-F0D6A2AA92C1Q34823693-21E9BB33-829A-40B4-B209-6B338C2BBF09Q34901665-57D9818B-B367-4706-8638-E5F4DA408197Q35102590-AEF0ABE9-1789-4D54-897E-6744B86860A8Q35649153-22E6F112-0F4B-4C2E-9DB3-E01945E97D4DQ36722761-6F490FF7-AC97-4CFE-949D-30B13ACC400EQ36802060-665FDA46-3DFE-47EF-9F70-C0386BFE828DQ38070363-C30C2DDD-5449-4DA1-AA22-86C92E4E9829Q38075961-49A7E6AA-4430-4320-803E-54A442F20E71Q38085068-1B624EA7-D070-41BD-B67D-CB57EEF52C55Q38340085-19B4C889-CE10-4512-9472-B230DF5B6732Q39781817-73294D76-54F4-445D-A3DC-4A0F7206694CQ41081392-0DEF7835-C7E0-4531-8B16-F10515230E0DQ41360901-53E4460C-F7AA-4B03-A1BD-A8FA8291A477Q42952867-69BE99FE-C6C9-4251-A79D-AAC8F3BA4FB3Q43536061-3E12FC4B-2CDE-440D-830F-F0C715BCF948Q43577283-995C481B-6F92-4936-BA24-A9EC4A76F4CEQ44491619-7054290C-7D1B-46AA-8FAA-D99BF43E388AQ45285312-A3383392-84E3-49A6-81AB-F6CA033A7ECAQ45328109-543DFBBA-A5CB-41A6-8DBB-FCC91DEDCD64Q46549136-F25CCD28-D6D5-4AEC-9130-A453BB999F0FQ51222196-F2FB14CA-49E8-4792-A6DB-9DEC5CD36339Q53479583-6DEEC38F-C0C5-4D5A-90F3-D40738CA0D0EQ54263702-CC226B71-1AC0-4140-83CF-4F29AB4DC462Q54307648-1D1AE98C-6737-4AF5-9606-DE82E90CCFA9Q54965289-DCB30055-F49C-4606-ACC5-D189294E52D3Q57703133-7778C290-8503-430B-9AA9-C85EA3C37D67Q64067558-C2409F1E-A700-4552-A4F1-B5A8D33D451AQ64092369-556E9F07-BAB0-438D-9B39-B128BD4DD6A4Q64093529-92A4B6E3-4831-40DC-A156-E6017F92B1A9Q64105305-9EC25344-BC27-4C73-ADD4-537E3D5B90B0Q85631083-B420FB46-1E96-483E-9375-F8D7BA6545C7Q85809327-EEC8562A-5267-4375-9A1C-9D878214430EQ85884223-AA487E92-514E-4AE0-A911-1299A487F49BQ86525469-B9A02D30-67C0-4BFA-9EE7-42669AE69689
P921
description
Arzneistoff
@de
Hợp chất hoá học
@vi
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
name
Rifaksimin
@sh
Rifaksimin
@sr
Rifaksymina
@pl
Rifaximin
@de
Rifaximin
@hu
Rifaximin
@nl
Rifaximin
@vi
Rifaximina
@es
Rifaximina
@it
rifaksimin
@nn
type
label
Rifaksimin
@sh
Rifaksimin
@sr
Rifaksymina
@pl
Rifaximin
@de
Rifaximin
@hu
Rifaximin
@nl
Rifaximin
@vi
Rifaximina
@es
Rifaximina
@it
rifaksimin
@nn
altLabel
C43H51N3O11
@it
Rifacol
@en
Rifamycin L 105
@en
Rifamycin L 105SV
@en
Rifaxidin
@en
Rifaximin
@en
Rifaximina
@en
Rifaximine
@en
Rifaximinum
@en
Rifaximinun
@en
prefLabel
Rifaksimin
@sh
Rifaksimin
@sr
Rifaksymina
@pl
Rifaximin
@de
Rifaximin
@hu
Rifaximin
@nl
Rifaximin
@vi
Rifaximina
@es
Rifaximina
@it
rifaksimin
@nn